CraniUS Therapeutics LLC, a privately held neurotechnology company, announced it has raised $20 million in Series B financing to accelerate development of NeuroPASS, a fully implantable, skull-embedded platform designed to bypass the blood-brain barrier (BBB) and enable targeted drug delivery and monitoring in the brain.

The Series B financing follows CraniUS's $20 million Series A round in 2022. The Series B includes $19 million from private investors and $1 million in non-dilutive funding from the State of Maryland, bringing total capital raised to approximately $40 million.

NeuroPASS is being developed as a multi-product platform, with an initial roadmap of three complementary products intended to progressively expand therapeutic capability. Together, these devices are intended to evolve cranial implants from passive reconstructive hardware into an active therapeutic interface capable of supporting long-term outpatient care.